Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001195649 | SCV001366045 | likely benign | Hereditary thrombocytopenia and hematologic cancer predisposition syndrome | 2020-04-10 | reviewed by expert panel | curation | This synonymous variant is predicted by SSF and MES to lead to either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created; in addition, evolutionary conservation prediction algorithms predict the site as not being highly conserved (PhyloP score 0.04 < 0.1[-14.1;6.4]) (BP4+BP7). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BP4 and BP7. |
Labcorp Genetics |
RCV000639535 | SCV000761110 | likely benign | Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 | 2023-01-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004957930 | SCV005495369 | likely benign | Inborn genetic diseases | 2024-12-04 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |